Rigel Pharmaceuticals (RIGL) EBIT (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly EBIT of $11.9 million for Q1 2026, down 6.95% year-over-year from $12.8 million in Q1 2025, and down 48.71% quarter-over-quarter from $23.2 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) EBIT (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' EBIT history runs 17 years deep, the most recent figure standing at $11.9 million for Q1 2026.
- In Q1 2026, EBIT fell 6.95% year-over-year to $11.9 million; the TTM figure through Mar 2026 stood at $124.6 million (up 183.58% YoY), while the FY2025 annual figure was $125.5 million, up 418.63% from the prior year.
- EBIT for Q1 2026 stood at $11.9 million, down from $23.2 million in the prior quarter.
- The five-year high for EBIT was $61.1 million in Q2 2025, with the low at -$26.3 million in Q1 2022.
- The 5-year median for EBIT is $2.0 million (2023), against an average of $5.0 million.
- The sharpest annual moves came in 2022 and 2025: EBIT tumbled 162.89% in 2022, then soared 13569.57% in 2025.
- Rigel Pharmaceuticals' EBIT stood at $2.1 million in 2022, then decreased by 5.44% to $2.0 million in 2023, then jumped by 747.15% to $16.7 million in 2024, then jumped by 39.12% to $23.2 million in 2025, then plunged by 48.71% to $11.9 million in 2026.
- Business Quant data shows RIGL's EBIT at $11.9 million in Q1 2026, $23.2 million in Q4 2025, and $28.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 23.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.58 Mn |
| Mar 31, 2026 | 11.89 Mn |
| Dec 31, 2025 | 23.17 Mn |
| Sep 30, 2025 | 28.42 Mn |
| Jun 30, 2025 | 61.10 Mn |
| Mar 31, 2025 | 12.77 Mn |
| Dec 31, 2024 | 16.66 Mn |
| Sep 30, 2024 | 14.06 Mn |
| Jun 30, 2024 | 447,000.00 |
| Mar 31, 2024 | -6.97 Mn |
| Dec 31, 2023 | 1.97 Mn |
| Sep 30, 2023 | -4.47 Mn |
| Jun 30, 2023 | -5.27 Mn |
| Mar 31, 2023 | -12.73 Mn |
| Dec 31, 2022 | 2.08 Mn |
| Sep 30, 2022 | -18.40 Mn |
| Jun 30, 2022 | -12.97 Mn |
| Mar 31, 2022 | -26.26 Mn |
| Dec 31, 2021 | -21.42 Mn |
| Sep 30, 2021 | -19.79 Mn |